calendar
4,005 catalysts · 3,921 phase readout · 2,127 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
next 91 dayslessmore
MonWedFri
4,005 catalysts · 3,921 phase readout · 2,127 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: GE HLTHCARE INC. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: GENENTECH INC. Form: TABLET. Route: ORAL
Sponsor: MANKIND PHARMA. Form: SOLUTION/DROPS. Route: OPHTHALMIC
Sponsor: RK PHARMA. Form: TABLET. Route: ORAL
Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION
Sponsor: EXTROVIS. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: QUAGEN. Form: SYRUP. Route: ORAL
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration
Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL
Sponsor: ACCORD HLTHCARE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: CAPSULE. Route: ORAL
Therapy area: Ophthalmology. Indication: Choroidal Neovascularization
Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy
Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion
Therapy area: Ophthalmology. Indication: Diabetic Retinopathy
Therapy area: Ophthalmology. Indication: Diabetic Macular Edema
Sponsor: NOVARTIS. Form: TABLET. Route: ORAL
Sponsor: University of Alberta. Phase: . Conditions: Low Back Pain
Sponsor: Beijing Sport University. Phase: NA. Conditions: Patellofemoral Pain
Sponsor: Definium Therapeutics US, Inc.. Phase: PHASE3. Conditions: Major Depressive Disorder
Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Unresectable Melanoma
Sponsor: The University of Queensland. Phase: NA. Conditions: Blood Culture Contamination, Infection
Sponsor: Mayo Clinic. Phase: . Conditions: Spontaneous Coronary Artery Dissection
Sponsor: Riphah International University. Phase: NA. Conditions: Adhesive Capsulitis of the Shoulder
Sponsor: October 6 University. Phase: NA. Conditions: Cerebral Palsy
Sponsor: Liverpool School of Tropical Medicine. Phase: NA. Conditions: Crimean-Congo Haemorrhagic Fever
Sponsor: Eilean Therapeutics AU Pty Ltd. Phase: PHASE1. Conditions: Healthy Volunteers
Sponsor: Chandan Sen. Phase: NA. Conditions: Wound Heal, Wound Infection, Wound Healing Delayed, Wound of Skin, Infections
Sponsor: National Institute of Mental Health (NIMH). Phase: . Conditions: Neuropsychiatric Disorder, Neurological Disorder, Neurodevelopmental Disorder, Sleep
Sponsor: University of Washington. Phase: NA. Conditions: Mental Health Disorder
Sponsor: Nanchang University. Phase: NA. Conditions: Natural Orifice Specimen Extraction Surgery, Robotic Surgery, Short-term Outcomes
Sponsor: Mayo Clinic. Phase: PHASE4. Conditions: Endometrial Carcinoma
Sponsor: Alumis Inc. Phase: PHASE1. Conditions: Healthy Volunteer